Liquid Biopsy Market Size Is Expected To Reach $5.96 Billion by 2030

Liquid Biopsy Sample Type (Blood, Urine) By Biomarker Type (CTC, ctDNA, Exosomes), By Technology (NGS, PCR)

Enhanced view of tumor provided by liquid biopsy technology is estimated to augment the market in coming years.

While tissue biopsies have been standard for cancer diagnosis for past several year, their highly invasive nature and frequently associated complications have been major concerns. Moreover, these biopsies lead to high expenditure being incurred by patients. Liquid biopsies, on the other hand, offer a less invasive methodology along with high effectiveness. Thus, there are a number of key private organizations involved in rigorous R&D activities for liquid biopsy test development and it is only a matter of time before these procedures grow in prominence in diagnostic paraphernalia of oncologists and pathologists.

Further key findings from the report suggest:

Technological developments such as electric field induced release and measurement (EFIRM)- Liquid Biopsy (eLB), which provides detection that can assist clinical treatment decisions for most common subtype of cancers are expected to drive the uptake of saliva based sampling over the forecast period

Currently, clinical use of isolation and detection technology is limited to CTC quantitation but the number of CTCs is found to hold significant correlation with disease severity. This is, thus, estimated to augment the market over the coming years

Rising awareness regarding advantages of multiple gene analysis along with the help of NGS is anticipated to support the growth of the market

Organizations such as American Society of Clinical Oncology (ASCO) are engaged in supporting implementation of liquid biopsy, which in turn is likely to spur the growth of the market

Intensifying competition between biotech companies and increasing investments by government in healthcare institutes will lead to development of more sophisticated tests

Companies engaged in R&D and commercialization of these products include Pathway Genomics; Natera Inc.; Epic Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom

Study Updates, Segment Specific & Country Level Reports, Free Sample Copy of This Report:- https://tinyurl.com/y4edue6w

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and healthcare.

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Info: www.grandviewresearch.com

This release was published on openPR.